EMA · European Union
alogliptin benzoate — EMA regulatory status
alogliptin benzoate (VIPIDIA) regulatory status in the European Union is tracked from public EMA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: EMA approved.
Status snapshot
- Status
- EMA approved
- Brand
- VIPIDIA
- Originator
- Takeda
- Mechanism
- Dipeptidyl peptidase IV inhibitor
- Target
- Dipeptidyl peptidase 4
- Structured fields
- 8
Sponsor / originator context: Takeda. Pipeline programs and exclusivity signals below are joined from ClinicalTrials.gov-linked projects and USPTO/EPO patent rows associated with this INN.
Pharmacology context used for competitive intelligence: Dipeptidyl peptidase IV inhibitor. Target: Dipeptidyl peptidase 4. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — EMA: approved.
Linked evidence on this spoke: 16 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| EMA | European Union | approved | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| Alogliptin | Phase 3 | Takeda | NCT01263496, NCT00328627 |
| Alogliptin | Phase 3 | Takeda | NCT01521962, NCT00306384 |
| Alogliptin Benzoate | Phase 3 | Takeda | NCT02856113 |
| Alogliptin and glimepiride | Phase 3 | Takeda | NCT01318083, NCT01318135 |
| Alogliptin and glyburide | Phase 3 | Takeda | NCT00286468 |
| Alogliptin and insulin | Phase 3 | Takeda | NCT00286429 |
| Alogliptin and metformin | Phase 3 | Takeda | NCT00286442 |
| Alogliptin and metformin | Phase 3 | Takeda | NCT01318109 |
| Alogliptin and pioglitazone | Phase 3 | Takeda | NCT01318070, NCT01318122 |
| Alogliptin and pioglitazone | Phase 3 | Takeda | NCT00286494, NCT00655863 |
| Alogliptin and voglibose | Phase 3 | Takeda | NCT01263483, NCT01263509 |
| Alogliptin | Phase 1 | Takeda | NCT02508168, NCT03501277 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 12421188 | Heterocyclic compound and use thereof | US |
| 12415782 | Heterocyclic compound and use thereof | US |
| 12409210 | CNS delivery of therapeutic agents | US |
| 12391760 | Method of treating primary sclerosing cholangitis | US |
| 12391765 | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies | US |
| 12383587 | AAV triple-plasmid system | US |
| 12384770 | Heterocyclic compound | US |
| 12378256 | Heterocyclic compound | US |
| 12358879 | Heterocyclic compound | US |
| 12337020 | Bacteriophage compositions | US |
| 12319940 | Methods for purification of arylsulfatase A | US |
| 12290531 | Compositions targeting BCMA and methods of use thereof | US |
Related hubs
FAQ
What is the EMA approval status of alogliptin benzoate?
alogliptin benzoate currently shows EMA approved in our European Union regulatory index. Confirm on the official EMA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get alogliptin benzoate regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to alogliptin benzoate?
This spoke lists 16 published programs associated with alogliptin benzoate in our pipeline index.